Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3025]

Gut microbiome disturbance by antibiotic treatment early in life is sufficient...

Dr Carolina Vicente-Dueñas - Institute of Biomedical Research of Salamanca...

Gut microbiome disturbance by antibiotic treatment early in life is sufficient to induce leukaemia in predisposed mice ( Dr Carolina Vicente-Dueñas - Institute of Biomedical Research of Salamanca, Salamanca, Spain )

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial...

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC ( Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )

Treating patients with multiple myeloma in the real world

Dr Ajai Chari and Prof Roman Hájek

Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or...

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )

New CAR T therapy for relapsed and refractory ALL

Dr Claire Roddie - University College London, London, UK

$New CAR T therapy for relapsed and refractory ALL ( Dr Claire Roddie - University College London, London, UK )$

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

Prof Philippe Moreau - University of Nantes, Nantes, France

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk...

Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy

LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera ( Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy )

ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute...

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

Maintenance treatment in multiple myeloma: A new era

Prof Sagar Lonial and Prof Wee-Joo Chng

Maintenance treatment in multiple myeloma: A new era ( Prof Sagar Lonial and Prof Wee-Joo Chng )

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into...

Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica...

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab ( Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, USA )

More from ecancer